Portal de Periódicos da CAPES

β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease

2005; Society for Neuroscience; Volume: 25; Issue: 40 Linguagem: Inglês

10.1523/jneurosci.1697-05.2005

1529-2401

Manuel Buttini, Eliezer Masliah, Robin Barbour, Henry Grajeda, Ruth Motter, Kelly Johnson‐Wood, Karen Khan, Peter Seubert, Stephen B. Freedman, Dale Schenk, Dora Games,

Neuroscience and Neuropharmacology Research

Alzheimer's disease neuropathology is characterized by key features that include the deposition of the amyloid β peptide (Aβ) into plaques, the formation of neurofibrillary tangles, and the loss of neurons and synapses in specific brain regions. The loss of synapses, and particularly the associated presynaptic vesicle protein synaptophysin in the hippocampus and association cortices, has been widely reported to be one of the most robust correlates of Alzheimer's disease-associated cognitive decline. The β-amyloid hypothesis supports the idea that Aβ is the cause of these pathologies. However, the hypothesis is still controversial, in part because the direct role of Aβ in synaptic degeneration awaits confirmation. In this study, we show that Aβ reduction by active or passive Aβ immunization protects against the progressive loss of synaptophysin in the hippocampal molecular layer and frontal neocortex of a transgenic mouse model of Alzheimer's disease. These results, substantiated by quantitative electron microscopic analysis of synaptic densities, strongly support a direct causative role of Aβ in the synaptic degeneration seen in Alzheimer's disease and strengthen the potential of Aβ immunotherapy as a treatment approach for this disease.